Alpha Tau Medical Ltd. - SIC # 3840 -

Ticker Exchange SIC # Website Latest Ticker
DRTS Nasdaq 3840 www.alphatau.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alpha Tau Medical Ltd.

Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specified Threshold for Success - Jul 21st, 2026 6:30 am
Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center - Jul 15th, 2026 6:30 am
New Strong Sell Stocks for July 7th - Jul 7th, 2026 6:31 am
New Strong Sell Stocks for July 2nd - Jul 2nd, 2026 1:49 am
Alpha Tau Medical’s (DRTS) First International Brain Cancer Use Tests The Breadth Of Its Alpha DaRT Platform - Jun 27th, 2026 1:06 pm
Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet - Jun 25th, 2026 9:35 am
Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel - Jun 23rd, 2026 6:30 am
Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control - Jun 11th, 2026 6:30 am
DRTS Stock Shot Up A Whopping 22% Today – Why A $196.5M Prostate Cancer Deal Got Investors Buzzing - Jun 3rd, 2026 8:52 am
Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients - Jun 3rd, 2026 6:30 am
Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting - Jun 1st, 2026 7:00 am
Alpha Tau Medical Sets Up Catalyst-Rich 2026 as Key Cancer Trial Data Nears - May 29th, 2026 7:03 am
Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update - May 18th, 2026 2:01 pm
Alpha Tau to Participate in May Investor Conferences - May 18th, 2026 6:30 am
Alpha Tau Medical Shares Early REGAIN Data: 2 Complete Responses in Glioblastoma Study - May 11th, 2026 8:07 am
Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET - May 11th, 2026 5:00 am
Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma - May 8th, 2026 7:10 am
Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma - May 8th, 2026 7:00 am
Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Italy with Alpha DaRT® at the University of Verona’s Pancreas Institute - May 7th, 2026 7:00 am
Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT® Head and Neck Cancer Combination with Pembrolizumab - May 5th, 2026 7:14 am